Irit Ben-Chelouche

Director of Business Development, Harvard Medical School

Displaying: 21 - 30 of 80 Results

Invention

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes. Professor David Liu and a multidisciplinary research team have recently discovered and optimized of a series of small molecules (<550 Da, IC50 = 1…

Investigators

  • David R. Liu
  • Juan Pablo Maianti

Invention

Therapeutic strategies for autism spectrum disorder sensory (tactile) hypersensitivity, anxiety and social interaction deficits

This is a novel strategy to treat tactile hypersensitivity, anxiety, and social interaction deficits by targeting the peripheral nervous system without drugging the brain.Autism spectrum disorders (ASDs), including Rett Syndrome, as well as Fragile…

Investigators

  • David Ginty
  • Lauren Orefice

Invention

A novel and effective technology for target-based screening

Target-based screening allows for rapid identification of ligands for an increasing number of macromolecular targets and is commonly used in drug discovery.The present invention uses interaction-dependent PCR (IDPCR) to selectively identify…

Investigators

  • David R. Liu
  • Christoph E. Dumelin
  • David J. Gorin
  • Lynn McGregor

Invention

Targeting spiral ganglion neurons for treatment of hearing loss

Hearing loss makes interactions with the world challenging for over 30 million people in the United States. While cochlear implants and hearing aid devices can ameliorate hearing loss, they often fail to restore the function of spiral ganglion…

Investigators

  • Lisa Goodrich

Invention

Genomic Analysis Tool Box

Cancer genomes frequently harbor high mutation rates, complex structural variations, and are characterized by genome instability. Detailed understanding of these characteristics of the cancer genome is necessary for pinpointing the cause of tumor…

Investigators

  • Peter Park

Invention

A system for in vivo generation of protective CD8+ T lymphocytes and other cells of hematopoietic origin

Differentiated CD8+ effector T cells mediate long-term immunity and protection against infectious diseases and cancer. Naive T cells are refractory to transduction with viral vectors without extensive ex vivo manipulations. A team of researchers at…

Investigators

  • Arlene H. Sharpe
  • Nicholas Haining

Invention

Immunology and Computational Biology Partnership

Professors Diane Mathis and Christophe Benoist at Harvard Medical School, together with other world-renowned immunologists and computational biologists from multiple research institutions, have created the Immunological Genome Project – Immgen…

Investigators

  • Diane J. Mathis
  • Christophe O. Benoist

Invention

Directed evolution of proteins and nucleic acids using nonhomologous random recombination

The nonhomologous random recombination (NRR) method allows portions of nucleic acids to be recombined at sites where there is little or no sequence homology. This increases the frequency at which novel sequences are generated, allowing a more…

Investigators

  • David R. Liu
  • Joshua Bittker

Invention

Drug-inducible RNA aptaswitch for regulating eukaryotic protein expression

Using in vivo evolution techniques, scientists in the Liu laboratory have engineered a drug-inducible aptaswitch for regulating eukaryotic protein expression at the transcription level. This aptaswitch consists of two modular RNA elements: a…

Investigators

  • David R. Liu
  • Allen R. Buskirk
  • Polina Kehayova

Invention

Small-molecule-triggered intein splicing as a universal switch for protein activation

Researchers in the laboratory of Professor David Liu have used directed evolution techniques to evolve an intein-based molecular switch that transduces binding of a small molecule into the activation of an arbitrary protein of interest. To create…

Investigators

  • David R. Liu
  • Allen R. Buskirk
  • Sun H. Peck

Page 3 of 8